Ranbaxy Laboratories Limited
19, Nehru Place
new Delhi
Tel: 91-11-6452666-72
Fax: ++91-11-6002076
Website: http://www.ranbaxy.com/
Email: seemaa@ranbaxy.co.in
218 articles about Ranbaxy Laboratories Limited
-
Ranbaxy Laboratories Release: Promising New Antimalarial Drug Demonstrates Significant Parasite Reduction In Patients
12/13/2005
-
U.S. Government Ready To Help The Ranbaxy Laboratories To Meet The Avian Flu Challenge
12/1/2005
-
Ranbaxy Laboratories Launches Two New Anti-HIV Products In India On World AIDS Day
12/1/2005
-
Court Of Appeals Upholds Preliminary Injunction Against Ranbaxy Laboratories, Enjoining Company From Marketing Quinapril HCl Tablets
11/23/2005
-
Ranbaxy Laboratories Consolidates Relationship With Japan JV Partner Nippon Chemiphar Co., Ltd.
11/11/2005
-
Ranbaxy Laboratories Wins On Atorvastatin Process Patent In Norway - Will Appeal Court Ruling On Intermediate Compound Patent
11/10/2005
-
Ranbaxy Laboratories Granted Permission To Appeal U.K. High Court Judgement On Patent Relating To Atorvastatin
11/3/2005
-
Microbia, Inc. Announces Second Collaboration Agreement Between Its Precision Engineering(TM) Unit And Ranbaxy Laboratories
11/1/2005
-
Ranbaxy Laboratories Clarifies 180-Day Exclusivities Relating To Pravastatin 80 Mg And Simvastatin 80 Mg Tablets
10/31/2005
-
Seven Indian AIDS Drugs Reinstated
8/19/2005
-
FDA Announces First Time Tentative Approval Of Indian Anti-AIDS Drugs
6/22/2005
-
Sughrue Mion Partner Leads Discussions On Patent Infringement And Intellectual Property In India
4/28/2005
-
Governmnent Tightens Access To Acne Drug
11/24/2004
-
Ranbaxy Announces Filing Of Anda Application For Anti-Retroviral Agent
10/29/2004
-
Indian Drug Makers' Quarterly Profits Seen Mixed
7/20/2004
-
FDA OKs Generic Antidotes For Anthrax
6/10/2004
-
Specialist Funds Swarm Over India's Drug Sector
6/7/2004
-
Ranbaxy USA Inc. Announces Launch Of DisperMox 600 Mg Strength
5/11/2004